N/A
Completed N=94
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
Source: ClinicalTrials.gov NCT01498692 ↗Enrolled (actual)
94
Serious AEs
28.7%
Results posted
Feb 2012
Primary outcomePrimary: Target Lesion Failure (TLF) — 2.4 percentage of participants — p=<0.0001
Summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions can be located in vessels that are smaller than average-sized.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Target Lesion Failure (TLF) |
0.0 | — |
| SECONDARY Target Lesion Failure (TLF) |
0.0 | — |
| SECONDARY Target Vessel Failure (TVF) |
0.0 | — |
| SECONDARY Myocardial Infarction (MI) Related to the Target Vessel |
0.0 | — |
| SECONDARY All Cause Mortality |
0.0 | — |
| SECONDARY Cardiac Death Related to the Target Vessel |
0.0 | — |
| SECONDARY Target Lesion Revascularization (TLR) |
2.1 | — |
| SECONDARY Target Lesion Revascularization TLR) |
0.0 | — |
| SECONDARY Target Vessel Revascularization (TVR) |
0.0 | — |
| SECONDARY Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition |
0.0 | — |
| SECONDARY Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition |
0.0 | — |
| SECONDARY Acute Technical Success |
96.8 | — |
| SECONDARY Clinical Procedural Success |
96.8 | — |
Eligibility Criteria
Inclusion Criteria
- Patient must be at least 18 years of age
- Patient (or legal guardian) understands study requirements and treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
- For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed
- Patient is eligible for percutaneous coronary intervention (PCI)
- Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris
- Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
- Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
- Patient is willing to comply with all protocol-required follow-up evaluations
Angiographic Inclusion Criteria (visual estimate):
- Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter ≥2.25 mm and 1.
Exclusion Criteria
- Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
- Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.
- Patients are excluded if any of the following criteria are met at time of the index procedure.
- If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of CK Total.
- If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
- If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.
- Troponin >1× ULN with at least one of the following.
- Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
- Development of pathological Q waves in the ECG; or
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.
- Patient has received an organ transplant or is on a waiting list for an organ transplant
- Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure
- Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
- Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
- Patient has platelet count 700,000 cells/mm3
- Patient has white blood cell (WBC) count <3,000 cells/mm3
- Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
- Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])
- Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
- Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure
- Target vessel(s) has been treated within 10 mm proximal or distal to ta
Data sourced from ClinicalTrials.gov (NCT01498692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.